Skip to main content

Advertisement

SpringerLink
Log in

Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study

  • Endocrine Trials
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

The aim of the study was to evaluate the effect of risedronate on bone mineral density (BMD) and bone turnover markers in HIV-infected osteoporotic males, according to their gonadal status. HIV patients were followed up for 24 months and divided into two groups: patients with osteoporosis or osteopenia with fractures (group A, n = 20) and those without (group B, n = 21). Group A and B were further divided according to the presence of reduced androgenizations. Both groups were treated with cholecalciferol 800 I.U. and calcium (Ca) 1,000 mg orally every day for the first 12 months. Risedronate 75 mg for two consecutive days a month orally was then added in group A, for another 12 months. Group B continued treatment with Ca and vitamin D. Every 6 months each patient underwent biochemical evaluation, and BMD measurement. A significant increase in lumbar BMD was observed in HIV males with adequate androgenization after 12 months of risedronate treatment in group A together with a reduction of bone turnover markers. BMD remained stable with a concomitant significant slight reduction of bone turnover markers in group B. Risedronate increased BMD and reduced bone turnover markers to a greater extent in patients with adequate androgenization compared to osteoporotic HIV males with symptomatic hypoandrogenization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. C. Cazanave, M. Dupon, V. Lavignolle-Aurillac, N. Barthe, S. Lawson-Ayayi, N. Mehsen, P. Mercié, P. Morlat, R. Thiébaut, F. Dabis, Groupe d’epidémiologie clinique du SIDA en aquitaine, Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 22, 395–402 (2008)

    Article  PubMed  Google Scholar 

  2. C. Torti, G. Mazziotti, P.A. Soldini, E. Focà, R. Maroldi, D. Gotti, G. Carosi, A. Giustina, High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41, 512–517 (2012)

    Article  PubMed  CAS  Google Scholar 

  3. V. Rochira, L. Zirilli, G. Orlando, D. Santi, G. Brigante, C. Diazzi, F. Carli, C. Carani, G. Guaraldi, Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One 6, e28512 (2011)

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. D.M. Wunder, N.A. Bersinger, C.A. Fux, N.J. Mueller, B. Hirschel, M. Cavassini, L. Elzi, P. Schmid, E. Bernasconi, B. Mueller, H. Furrer, Swiss HIV Cohort Study, Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir. Ther. 12, 261–265 (2007)

  5. A. Bonjoch, M. Figueras, C. Estany, N. Perez-Alvarez, J. Rosales, L. del Rio, S. di Gregorio, J. Puig, G. Gómez, B. Clotet, E. Negredo, Osteoporosis Study Group, High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 24, 2827–2833 (2010)

  6. M.J. Bolland, T.K. Wang, A. Grey, G.D. Gamble, I.R. Reid, Stable bone density in HAART-treated individuals with HIV: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 2721–2731 (2011)

    Article  PubMed  CAS  Google Scholar 

  7. J. Huang, L. Meixner, S. Fernandez, J.A. McCutchan, A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 23, 51–57 (2009)

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. S. Rozenberg, E. Lanoy, M. Bentata, J.P. Viard, M.A. Valantin, P. Missy, I. Darasteanu, C. Roux, S. Kolta, D. Costagliola, ANRS 120 Fosivir Study Group, Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week Trial (ANRS 120). AIDS Res. Hum. Retrovir. 28, 972–980 (2012)

    PubMed  CAS  Google Scholar 

  9. H. Taggart, M.A. Bolognese, R. Lindsay, M.P. Ettinger, H. Mulder, R.G. Josse, A. Roberts, H. Zippel, S. Adami, T.F. Ernst, K.P. Stevens, Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin. Proc. 77, 262–270 (2002)

    Article  PubMed  CAS  Google Scholar 

  10. R.A. Adler, Osteoporosis in men: recent progress. Endocrine 44, 40–46 (2013)

    Article  PubMed  CAS  Google Scholar 

  11. F. Cosman, Is there a role for combination therapy for osteoporosis? Endocrine 44, 5–7 (2013)

    Article  PubMed  CAS  Google Scholar 

  12. M.D. Walker, N.E. Cusano, J. Sliney Jr, M. Romano, C. Zhang, D.J. McMahon, J.P. Bilezikian, Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine 44, 237–246 (2013)

    Article  PubMed  CAS  Google Scholar 

  13. M. Caron-Debarle, C. Lagathu, F. Boccara, C. Vigouroux, J. Capeau, HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol. Med. 16, 218–229 (2010)

    Article  PubMed  CAS  Google Scholar 

  14. A. Sharma, P.L. Flom, J. Weedon, R.S. Klein, Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS 24, 2337–2345 (2010)

    Article  PubMed  PubMed Central  Google Scholar 

  15. J. Pepe, M.T. Petrucci, M.L. Mascia, S. Piemonte, V. Fassino, E. Romagnoli, S. Minisola, The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance. Calcif. Tissue Int. 82, 418–426 (2008)

    Article  PubMed  CAS  Google Scholar 

  16. R. Iuliano, G. Forastieri, M. Brizzi, L. Mecocci, F. Mazzotta, L. Ceccherini-Nelli, HIV-plasma viral load detection by branched DNA signal amplification. New Microbiol. 18, 299–301 (1995)

    PubMed  CAS  Google Scholar 

  17. J. Manasa, H. Musabaike, C. Masimirembwa, E. Burke, R. Luthy, J. Mudzori, Evaluation of the Partec flow cytometer against the BD FACSCalibur system for monitoring immune responses of human immunodeficiency virus-infected patients in Zimbabwe. Clin. Vaccine Immunol. 14, 293–298 (2007)

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. A. Aversa, R. Bruzziches, D. Francomano, G. Rosano, A.M. Isidori, A. Lenzi, G. Spera, Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged Men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind. J. Sex Med. 10, 3495–3503 (2010)

    Article  Google Scholar 

  19. C.Y. Genant, C. van Wu, M.C. Kuijk, Nevitt, vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 9, 1137–1148 (1993)

    Google Scholar 

  20. M. Pedrazzoni, G. Girasole, F. Bertoldo, G. Bianchi, C. Cepollaro, A. Del Puente, S. Giannini, S. Gonnelli, D. Maggio, C. Marcocci, S. Minisola, E. Palummeri, M. Rossini, L. Sartori, L. Sinigaglia, Definition of a population-specific DXA reference standard in Italian Women: the densitometric Italian normative study (DINS). Osteoporos. Int. 14, 978–982 (2003)

    Article  PubMed  CAS  Google Scholar 

  21. I. Daig, L.A. Heinemann, S. Kim, S. Leungwattanakij, X. Badia, E. Myon, C. Moore, F. Saad, P. Potthoff, M. Thai do, The aging Males’ symptoms (AMS) scale: review of its methodological characteristics. Health Qual. Life Outcomes 15, 1–77 (2003)

    Google Scholar 

  22. J. Pepe, A.M. Isidori, M. Falciano, G. Iaiani, A. Salotti, D. Diacinti, R. Del Fiacco, E. Sbardella, C. Cipriani, S. Piemonte, E. Romagnoli, A. Lenzi, S. Minisola, The combination of frax and aging male symptoms scale better identifies treated Hiv males at risk for major fracture. Clin. Endocrinol. (Oxf) 77, 672–678 (2012)

    Article  Google Scholar 

  23. O. Moreno-Pérez, C. Escoín, C. Serna-Candel, J. Portilla, V. Boix, R. Alfayate, V. González-Sánchez, M. Mauri, J. Sánchez-Payá, A. Picó, The determination of total testosterone and free testosterone (RIA) are not applicable to the evaluation of gonadal function in HIV-infected Males. J. Sex. Med. 7, 2873–2883 (2010)

    Article  PubMed  Google Scholar 

  24. K. Izumi, A. Mizokami, K. Sugimoto, K. Narimoto, S. Miwa, Y. Maeda, Y. Kadono, M. Takashima, E. Koh, M. Namiki, Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 73, 1342–1346 (2009)

    Article  PubMed  Google Scholar 

  25. E.G. de Menezes Barbosa, F.J. de Paula, A.A. Machado, F. de Assis Pereira, F. Barbosa Jr, A.M. Navarro, Impact of antiretroviral therapy on bone metabolism markers in HIV-seropositive patients. Bone 57, 62–67 (2013)

    Article  PubMed  Google Scholar 

  26. E. Orwoll, C.S. Teglbjærg, B.L. Langdahl, R. Chapurlat, E. Czerwinski, D.L. Kendler, J.Y. Reginster, A. Kivitz, E.M. Lewiecki, P.D. Miller, M.A. Bolognese, M.R. McClung, H.G. Bone, Ö. Ljunggren, B. Abrahamsen, U. Gruntmanis, Y.C. Yang, R.B. Wagman, S. Siddhanti, A. Grauer, J.W. Hall, S. Boonen, A randomized, placebo-controlled study of the effects of denosumab for the treatment of Men with low bone mineral density. J. Clin. Endocrinol. Metab. 97, 3161–3169 (2012)

    Article  PubMed  CAS  Google Scholar 

  27. E. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, S. Adami, K. Weber, R. Lorenc, P. Pietschmann, K. Vandormael, A. Lombardi, Alendronate for the treatment of osteoporosis in men. New Engl. J. Med. 31, 604–610 (2000)

    Article  Google Scholar 

  28. F. Zengerling, A.J. Schrader, M.V. Cronauer, H. Stemann, M. Schrader, L. Rinnab, The “aging Males’ symptoms” scale (AMS): predictive value for lowered circulating androgens. Aging Male 15, 253–257 (2012)

    Article  PubMed  CAS  Google Scholar 

  29. V. Carnevale, E. Romagnoli, C. Cipriani, R. Del Fiacco, S. Piemonte, J. Pepe, A. Scillitani, S. Minisola, Sex hormones and bone health in males. Arch. Biochem. Biophy. 503, 110–117 (2010)

    Article  CAS  Google Scholar 

  30. A. Haider, U. Meergans, A. Traish, F. Saad, G. Doros, P. Lips, L. Gooren, Progressive improvement of T-scores in Men with osteoporosis and subnormal serum testosterone levels upon treatment with testosterone over six years. Int. J. Endocrinol. 2014, 496948 (2014)

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Nothing to declare

Disclosure

At present Dr Romano Del Fiacco is working in the Medical Direction team of Eli-Lilly, Italy. The other authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Medical Disciplines, “Sapienza” University, Viale Del Policlinico 155, 00161, Rome, Italy

    J. Pepe, R. Del Fiacco, C. Cipriani, S. Piemonte, O. Raimo, P. Biondi, F. Biamonte & S. Minisola

  2. Department of Experimental Medicine, “Sapienza” University, Rome, Italy

    A. M. Isidori, E. Sbardella & A. Lenzi

  3. Department of Public Health and Infectious Diseases, “Sapienza” University, Rome, Italy

    M. Falciano, G. Iaiani & A. Salotti

  4. Department of Radiology, “Sapienza” University, Rome, Italy

    D. Diacinti

Authors
  1. J. Pepe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. M. Isidori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Falciano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Iaiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Salotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Diacinti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Del Fiacco
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Sbardella
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Cipriani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Piemonte
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. O. Raimo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. P. Biondi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. F. Biamonte
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A. Lenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. S. Minisola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Pepe.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pepe, J., Isidori, A.M., Falciano, M. et al. Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study. Endocrine 47, 456–462 (2014). https://doi.org/10.1007/s12020-014-0349-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-014-0349-0

Keywords

Search

Navigation